StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Iovance Biotherapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Iovance Biotherapeutics's profit margin for the twelve months ending Jun 30, 2026 was -89.1%. For fiscal 2025 it was -148.4%, against -226.8% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-148.4%+78.5
FY2024Dec 31, 2024-226.8%+37118.6
FY2023Dec 31, 2023-37345.4%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-47.6%+138.6
Q1 FY2026Mar 31, 2026-110.7%+124.8
Q4 FY2025Dec 31, 2025-82.9%+23.7
Q3 FY2025Sep 30, 2025-135.3%+7.4
Q2 FY2025Jun 30, 2025-186.2%+125.9
Q1 FY2025Mar 31, 2025-235.5%+15565.3
Q4 FY2024Dec 31, 2024-106.6%+24038.4
Q3 FY2024Sep 30, 2024-142.7%+24113.2
Q2 FY2024Jun 30, 2024-312.2%+44447.5
Q1 FY2024Mar 31, 2024-15800.8%–
Q4 FY2023Dec 31, 2023-24145.0%–
Q3 FY2023Sep 30, 2023-24255.9%–
Q2 FY2023Jun 30, 2023-44759.7%–

More Iovance Biotherapeutics figures

See a number that looks wrong?